bioMerieux Revenue and Competitors
Estimated Revenue & Valuation
- bioMerieux's estimated annual revenue is currently $2.2B per year.
- bioMerieux's estimated revenue per employee is $155,000
Employee Data
- bioMerieux has 13886 Employees.
- bioMerieux grew their employee count by 7% last year.
bioMerieux's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Digital Transformation Product Owner | Reveal Email/Phone |
2 | Product owner | Reveal Email/Phone |
3 | Corporate VP, Manufacturing & Supply Chain | Reveal Email/Phone |
4 | Sr. VP, Global Health Data Insights | Reveal Email/Phone |
5 | Chief System Architect | Reveal Email/Phone |
6 | Chief Staff, Clinical Operations LatAm | Reveal Email/Phone |
7 | Corporate VP, Asia Pacific Region,Group Portfolio & Strategic Planning | Reveal Email/Phone |
8 | Chief Staff Europe & Middle East | Reveal Email/Phone |
9 | Sr. VP Site Operations Americas | Reveal Email/Phone |
10 | General Secretary, Corporate VP, Human Resources and Communications | Reveal Email/Phone |
bioMerieux Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20250M | 54574 | 4% | $39M | $74.9B |
What Is bioMerieux?
Pioneering Diagnostics\n\nA world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. \n\nIn 2019, revenues reached €2.7 billion, with over 90% of international sales. \nbioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. \n\nIts products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. \n\nbioMérieux is listed on the Euronext Paris stock market.\n\nSymbol: BIM – ISIN Code: FR0013280286\nReuters: BIOX.PA/Bloomberg: BIM.FP
keywords:N/A
N/A
Total Funding
13886
Number of Employees
$2.2B
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
bioMerieux News
bioMérieux (OTCMKTS:BMXMF) Raised to Hold at Zacks Investment Research. Posted by admin on Apr 25th, 2022. Share on Twitter Share on Facebook Share on...
Worldwide Flow Cytometry Industry to 2025 - Featuring bioMerieux Diagnostics, Bio-Rad Laboratories and Cytek Biosciences Among Others.
NEW YORK BioMérieux on Tuesday announced it has entered into an agreement to acquire Specific Diagnostics for an acquisition price...
bioMérieux - Third-Quarter 2021 Business Review Organic growth of 12.1% at constant exchange rates and scope of consolidation over the first nine months of the year: €2,452 million in sales Up 8.2% as reported Q3 sales organic growth at 11.6%, significantly above expectations due to a s ...
“Every lab we encounter wants rapid, easy-to-use susceptibility testing at the right price; we couldn’t reach them all without partnering with an organization with the scale and quality of bioMérieux,” said Paul A. Rhodes, Ph.D., CEO of Specific. SAN JOSE, Calif. (PRWEB) June 29, 2021 In the c ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 15435 | 6% | $68.7M |